Oseffyl (Teriparatide)

Teriparatide mimics the first 34 amino acids of natural parathyroid hormone. It binds to PTH1 receptors on bone‑forming cells, activating signaling pathways that increase osteoblast activity, stimulate new bone formation, and improve overall bone strength.

The dosing regimen for Oseffyl is determined by the prescribing clinician based on the patient’s condition, weight, and treatment goals. The prescriber will select the appropriate dose and administration schedule.

Teriparatide is generally contraindicated during pregnancy and lactation unless the potential benefits outweigh the risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Oseffyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Unlike anti‑resorptive agents such as bisphosphonates, teriparatide is an anabolic therapy that actively stimulates new bone formation. It is typically reserved for patients who have not responded adequately to other treatments or who have severe bone loss.

Oseffyl must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain logistics are essential to maintain product stability.

Oseffyl is supplied as a sterile solution for subcutaneous injection. The injection is usually given once daily in the thigh or abdomen, following the technique and site‑rotation guidelines provided by the prescribing physician.

The most serious potential risks include the rare development of osteosarcoma, severe hypercalcemia, and severe allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions.

Oseffyl should not be used by individuals with a history of bone radiation therapy, those with hyperparathyroidism, patients who are pregnant or breastfeeding unless absolutely necessary, and anyone who has experienced a severe allergic reaction to teriparatide or any component of the formulation.